Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized blinded dose-comparison study of LetibotulinumtoxinA for horizontal forehead lines
2024-512349-17-00Phase 2Completed
- Sponsor
- Croma-Pharma
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in Forehead lines (3 arms), sponsored by Croma-Pharma. Primary endpoint: Week 4 responder rate by CDFLAS. Started Oct 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Forehead lines
Beyond the preview
Go deeper on 2024-512349-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512349-17-00.